BioCryst Pharmaceuticals (NASDAQ: BCRX) and Cellular Biomedicine Group (NASDAQ:CBMG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares BioCryst Pharmaceuticals and Cellular Biomedicine Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -160.97% -276.62% -44.43%
Cellular Biomedicine Group -12,736.68% -41.33% -39.53%

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 3.37, indicating that its stock price is 237% more volatile than the S&P 500. Comparatively, Cellular Biomedicine Group has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Cellular Biomedicine Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 0 3 7 0 2.70
Cellular Biomedicine Group 0 0 1 0 3.00

BioCryst Pharmaceuticals presently has a consensus target price of $9.25, suggesting a potential upside of 92.71%. Cellular Biomedicine Group has a consensus target price of $18.00, suggesting a potential upside of 87.50%. Given BioCryst Pharmaceuticals’ higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Cellular Biomedicine Group.

Insider & Institutional Ownership

70.2% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 5.8% of Cellular Biomedicine Group shares are held by institutional investors. 5.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Cellular Biomedicine Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and Cellular Biomedicine Group’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
BioCryst Pharmaceuticals $29.28 million 13.18 -$42.94 million ($0.62) -7.74
Cellular Biomedicine Group $229,178.00 590.97 -$22.45 million ($2.04) -4.71

Cellular Biomedicine Group has higher revenue, but lower earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellular Biomedicine Group, indicating that it is currently the more affordable of the two stocks.

Summary

BioCryst Pharmaceuticals beats Cellular Biomedicine Group on 7 of the 13 factors compared between the two stocks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.